Previous 10 | Next 10 |
Peloton Therapeutics, Inc. ( PLTX ) is at an advanced stage of development, which will please many investors. The company expects to start patient enrollment for its Phase 3 clinical trial in the second half of 2019. Additionally, three years ago, competitors were valued at $250-500 million in...
Takeda Pharmaceutical (NYSE: TAK ) inks an agreement with privately held Curadev for the rights to CRD5500, its lead small molecule Stimulator of Interferon Genes (STING) agonist for the potential treatment of solid tumors. More news on: Takeda Pharmaceutical Company Limited, Tril...
Gainers: Attis Industries (NASDAQ: ATIS ) +49% . MACOM Technology Solutions Holdings (NASDAQ: MTSI ) +28% . Akorn (NASDAQ: AKRX ) +28% . Chanticleer Holdings (NASDAQ: BURG ) +26% . Corindus Vascular Robotics (NYSEMKT: CVRS ) +21% . Avalara (NYSE: AVLR ) +20% . Conformis (NASDAQ...
Aduro Biotech (NASDAQ: ADRO ): Q1 GAAP EPS of -$0.29 misses by $0.10 . More news on: Aduro BioTech, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
BERKELEY, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of ca...
BERKELEY, Calif., April 18, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical stage biopharmaceutical company developing therapies in the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways, today announced the appointment of Fra...
BERKELEY, Calif., April 17, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical stage biopharmaceutical company developing therapies in the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways, today announced that abstracts pertain...
The following slide deck was published by Aduro BioTech, Inc. in conjunction with this Read more ...
Trillium Therapeutics ( TRIL -4.4% ) has added a STING (stimulator of interferon genes) agonist program to its pipeline named TTI-10001, a development that apparently lacks investor enthusiasm. More news on: Trillium Therapeutics Inc., Merck & Co., Inc., Bristol-Myers Squibb Compan...
BERKELEY, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled to present at the H.C. Wainwright Global Life Sciences Conference in London, United Kingdom ...
News, Short Squeeze, Breakout and More Instantly...
Aduro Biotech Inc. Company Name:
ADRO Stock Symbol:
NASDAQ Market:
The 15th Annual Global CSR & ESG Awards Honours 2023 Winners DA NANG, VIETNAM, Aug 30, 2023 - (ACN Newswire) - The 15th Annual Global CSR & ESG Summit & Awards ended on a high note before a full house in Da Nang, Vietnam, on August 28. Organized at the Novotel Danang Pre...
Combined Company Will H ave Over $275 Million in Operating Capital and Trade on Nasdaq under the Ticker Symbol “KDNY” VANCOUVER, British Columbia and SEATTLE, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Chinook Therap...
One-for-Five Reverse Stock Split to be Effective October 2, 2020 BERKELEY, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADURO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (ST...